Saunders' latest spell as CEO started in 2023, as Bausch Health worked to spin Bausch + Lomb out as an independent public ...

Bristol Myers Squibb has reported phase 3 results with a new type of drug for idiopathic pulmonary fibrosis (IPF) that could ...

Operational review meeting minutes released by the Department of Health and Social Care (DHSC) reveal that the industry and ...

Expectations for Wnt pathway-targeting trispecific antibody remigromig (MK-3000, formerly known as EYE103) were riding high ...

AstraZeneca has already filed for approval of its therapy for ultra-rare disease hypophosphatasia (HPP), after missing the ...

A study has shown that the efficacy of Eli Lilly's psoriasis therapy Taltz is improved when it is given in combination with ...

Asahi Kasei's $920 million takeover of German biotech Aicuris in April has paid off with FDA approval for the herpes simplex ...

For years, medtech companies have treated the digital experience around their devices as an afterthought. A layer of software ...

While still in the early stages of development, in vivo CAR-T therapies have generated excitement about their potential as cancer therapies, and updates from a couple of class pioneers at ASCO will ...

MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...

The steady stream of M&A deals in pharma this year has continued with the news that GSK has agreed to buy Canada's 35Pharma and its drug candidate for pulmonary hypertension (PH) for $950 million. The ...

As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira ...